Iovanace Biotherapeutics (IOVA) PT Lowered to $13 at Stifel, Buy Rating Maintained, "Stock Reaction Seems Overdone"
Tweet Send to a Friend
Stifel analyst Benjamin Burnett lowered the price target on Iovanace Biotherapeutics (NASDAQ: IOVA) to $13.00 (from $26.00) while maintaining a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
